Please assess the completion status of the following clinical trial:

Trial Title: Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Age \> 18 years~* Need for invasive mechanical ventilation~* Confirmed inhalation trauma (bronchoscopically)~Exclusion Criteria:~* \> 36 hours after trauma~* Receiving invasive ventilation \> 24 hours~* Expected duration of mechanical ventilation \< 24 hours~* Chronic obstructive pulmonary disease GOLD stage III and IV~* Any history of pulmonary hemorrhage in the past 3 months~* Any history of significant bleeding disorder~* Known allergy to heparin, including heparin-induced thrombocytopenia~* Pregnancy or breast feeding~* Unlikely to survive for \> 72 hours~* Total body surface area (TBSA) \> 60%~* Witnessed or proven aspiration (i.e., confirmed by bronchoscopy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- unfractionated heparin (Type: EXPERIMENTAL): 25.000 IU/5 ml, will be nebulized 4 hourly (i.e. 6 times daily)
- placebo (Type: PLACEBO_COMPARATOR): Sterile sodium chloride (NaCl 0.9%, Pfizer), in 5 ml, will be nebulized every 4 hours (i.e. 6 times daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).